<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03381352</url>
  </required_header>
  <id_info>
    <org_study_id>Y-MX2015-014</org_study_id>
    <nct_id>NCT03381352</nct_id>
  </id_info>
  <brief_title>Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer</brief_title>
  <official_title>Phase II Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and adverse events of intensity
      modulated radiation therapy (IMRT) concurrent with chemotherapy for anal squamous carcinoma.
      All enrolled anal squamous carcinoma patients are intented to receive IMRT concurrent with
      Capecitabine + mitomycin Â± cetuximab targeted therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>8 weeks after IMRT</time_frame>
    <description>To evaluate response rate of IMRT with chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>from start of IMRT to 8 weeks after IMRT</time_frame>
    <description>To assess the adverse events of IMRT with chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Anal Cancer</condition>
  <arm_group>
    <arm_group_label>Chemo-radiotherapy with IMRT technique</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy with IMRT technique concurrent with Capecitabine and MMC chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Chemo-radiotherapy with IMRT technique</intervention_name>
    <description>IMRT radiation technique; 50.4-54Gy/25F</description>
    <arm_group_label>Chemo-radiotherapy with IMRT technique</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 825mg/m2 PO BID</description>
    <arm_group_label>Chemo-radiotherapy with IMRT technique</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin C</intervention_name>
    <description>Mitomycin C 10mg/m2 D1,29 iv</description>
    <arm_group_label>Chemo-radiotherapy with IMRT technique</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CT/MRI diagnosed stage cT1-4N0-3;

          -  Histologically confirmed anal squamous carcinoma;

          -  KPS &gt;= 70

          -  Adequate organ function;

          -  No previous radiotherapy or chemotherapy;

          -  No surgery.

        Exclusion Criteria:

          -  Previous malignant cancer history;

          -  Allegic to 5-fu or MMC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ning Li, MD</last_name>
    <phone>0086-13810381399</phone>
    <email>lee_ak@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese academy of medical sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning Li, MD</last_name>
      <phone>0086-13810381399</phone>
      <email>lee_ak@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2017</study_first_submitted>
  <study_first_submitted_qc>December 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2017</study_first_posted>
  <last_update_submitted>January 28, 2018</last_update_submitted>
  <last_update_submitted_qc>January 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>LI Ning</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>Anal cancer</keyword>
  <keyword>IMRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anus Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

